AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca total U.S. Gross-to-Net (GTN) deductions from gross product sales ($M) ($M)
Form 20-F Note 2 — U.S. Gross-to-Net Sales Rebates, Chargebacks & Returns
Latest, FY2025
23,941
Period ended Dec 31, 2025
Change on a year earlier
+26.1%
18,986 in FY2024
History
2 years
Since FY2024
Sources
1
Form 20-F FY2025 Annual Report
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total U.S. Gross-to-Net (GTN) deductions from gross product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23,941 | +26.1% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 18,986 | – | Form 20-F FY2025 Annual Report ↗ |
Breakdown
What makes up total u.s. gross-to-net (gtn) deductions from gross product sales ($m)
- Managed Care, Medicare Part D & commercial rebates ($M)13,963 · FY2025
- Chargebacks & 340B / government contract discounts ($M)5,113 · FY2025
- Medicaid & state supplemental rebates ($M)2,527 · FY2025
- Cash & prompt-pay wholesaler discounts ($M)483 · FY2025
- Customer product returns provision ($M)149 · FY2025
- U.S. Branded Prescription Drug (BPD) fee ($M)99 · FY2025
- Other U.S. patient assistance & co-pay card deductions ($M)1,607 · FY2025
Cite this data
StockData. (2026). AstraZeneca Total U.S. Gross-to-Net (GTN) deductions from gross product sales ($M) ($M), annual FY2024–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/us_gtn_ded_total
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.